New hope for hemophilia a: phase 3 trial launches for Next-Gen bleed prevention
NCT ID NCT07416604
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 4 times
Summary
This study compares a new drug, NXT007, to an existing one (emicizumab) for preventing bleeding episodes in people aged 12 and older with hemophilia A. Participants may have severe, moderate, or mild disease, with or without factor VIII inhibitors. The goal is to see if NXT007 is more effective at reducing bleeds and improving quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Auckland City Hospital
RECRUITINGAuckland, 1023, New Zealand
-
Azienda Ospedaliera Universitaria Careggi
RECRUITINGFlorence, Tuscany, 50134, Italy
-
Center for Inherited Blood Disorders
RECRUITINGOrange, California, 92868, United States
-
Debreceni Egyetem Klinikai Kozpont Nagyerdei Campus
RECRUITINGDebrecen, Pest County, 4032, Hungary
-
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
RECRUITINGMilan, Lombardy, 20122, Italy
-
Gunma University Hospital
RECRUITINGMaebashi, Gunma, 371-8511, Japan
-
Hospices Civils de Lyon
RECRUITINGBron, 69500, France
-
Hospital Regional Universitario de Malaga ? Hospital General
RECRUITINGMálaga, 29010, Spain
-
Hospital Universitari i Politecnic La Fe de Valencia
RECRUITINGValencia, 46026, Spain
-
Hospital Universitario La Paz - PPDS
RECRUITINGMadrid, 28046, Spain
-
Hospital Universitario Vall d'Hebron - PPDS
RECRUITINGBarcelona, 08035, Spain
-
Hospital Universitario Virgen del Rocio - PPDS
RECRUITINGSeville, 41013, Spain
-
Hospital de la Santa Creu i Sant Pau
RECRUITINGBarcelona, 08041, Spain
-
IRCCS Istituto Clinico Humanitas
RECRUITINGRozzano, Lombardy, 20089, Italy
-
Innovative Hematology, Inc.
RECRUITINGIndianapolis, Indiana, 46260, United States
-
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, 301617, China
-
Kyungpook National University Hospital
RECRUITINGDaegu, 41944, South Korea
-
Nagoya University Hospital
RECRUITINGNagoya, Aiti, 466-8560, Japan
-
Nara Medical University Hospital
RECRUITINGKashihara-shi, Nara, 634-8522, Japan
-
National Taiwan University Hospital
RECRUITINGTaipei, 10002, Taiwan
-
Ogikubo Hospital
RECRUITINGSuginami-Ku, Tokyo, 167-0035, Japan
-
St Joseph's Children's Hospital of Tampa
RECRUITINGTampa, Florida, 33607-6307, United States
-
The Chaim Sheba Medical Center - PPDS
RECRUITINGRamat Gan, Central District, 5262100, Israel
-
UZ Leuven
RECRUITINGLeuven, Antwerp, 3000, Belgium
-
Universitair Medisch Centrum Utrecht Cancer Center - PPDS
RECRUITINGUtrecht, 3584 CX, Netherlands
-
University Hospital of Wales
RECRUITINGCardiff, CF14 4XW, United Kingdom
-
University Of Iowa Hospitals And Clinics
RECRUITINGIowa City, Iowa, 52242-1009, United States
-
University of Colorado Hemophilia and Thrombosis Center
RECRUITINGAurora, Colorado, 80045-7202, United States
-
Universitätsklinikum Bonn
RECRUITINGBonn, North Rhine-Westphalia, 53127, Germany
-
Washington Center for Bleeding Disorders
RECRUITINGSeattle, Washington, 98101-3932, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A Once-a-Week shot could transform hemophilia Care—Even for those with inhibitors
- Can a new clotting factor offer better bleed protection for severe hemophilia?
- Do newer hemophilia drugs protect joints better? study aims to find out
- Newborn screening study aims to catch rare diseases at birth
- Could home blood tests transform hemophilia care? study seeks patient views
- New clotting factor shows promise for hemophilia a bleeds